ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Phase III Investigational Trial of NUBEQA® in Combination with Docetaxel and Androgen Deprivation Therapy Increases Overall Survival in Patients with mHSPC
December 06, 2021The Phase III ARASENS trial investigating the use of the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) in metastatic hormone-sensitive prostate cancer (mHSPC) has met its primary endpoint. In the ARASENS trial, NUBEQA in combination... -
Athenex Announces License Agreement with PharmaEssentia for Oradoxel (Oral Formulation of Docetaxel) in Several Areas in Asia
December 03, 2018Athenex, Inc., a global biopharmaceutical company dedicated to the research of new therapies for cancer and related diseases, Development and commercialization......
Pharma Sources Insight January 2025
